Evidence-based peptide information for research and educational purposes only.
Navaro NavaroCompound library, calculators & guides
GH Secretagogues

CJC-1295 (No DAC / Modified GRF 1-29)

← Back to Library
Protocol not independently verified FDA safety flag GH Axis
Educational reference only. Read the full disclaimer. The protocols below are not automatically an FDA-approved or clinically verified regimen unless explicitly marked as label-verified or human-trial protocol above.

Overview

Route(s): Subcutaneous

Typical vial sizes: 2, 5, 10 mg

Dosing window: Pre-Bed Fasted

Receptor / target: GHRH

Properties: GH Secretagogue

Pre-mixed: No

Protocol examples

Standard Protocol

TimeframeDoseNotes
Weeks 1-12100mcg once dailyAdministered right before bed. Must be fasted for 2+ hours.

Protocol example from the source dataset; verify against the evidence status and listed sources.

Alternative Titration 1

TimeframeDoseNotes
Weeks 1-2100 mcg 1x DailyAt bedtime fasted.
Weeks 3-4150 mcg 1x DailyAt bedtime fasted.
Weeks 5-6200 mcg 1x DailyAt bedtime fasted.
Weeks 7-12250-300 mcg 1x DailyAt bedtime fasted.

Alternative example from the source dataset; not an approved-label regimen unless marked above.

Alternative Titration 2 (Low-Dose / Anti-Aging)

TimeframeDoseNotes
Weeks 1-4100mcg 1x DailyAt bedtime fasted.
Weeks 5-12150mcg 1x DailyAt bedtime fasted.

Alternative example from the source dataset; not an approved-label regimen unless marked above.

Alternative Titration 3 (2x/Day Protocol)

TimeframeDoseNotes
Week 1100 mcg 2x/dayAM/PM fasted.
Weeks 2-4200 mcg 2x/dayAM/PM fasted.
Weeks 5-8300 mcg 2x/dayAM/PM fasted.

Alternative example from the source dataset; not an approved-label regimen unless marked above.

Alternative Titration 4 (3x/Day Protocol)

TimeframeDoseNotes
Days 1-3150 mcg 3x/dayAM/PM fasted, MidDay post meal.
Days 4-7200 mcg 3x/dayAM/PM fasted, MidDay post meal.
Weeks 2-3300 mcg 3x/dayAM/PM fasted, MidDay post meal.
Weeks 4-6400 mcg 3x/dayAM/PM fasted, MidDay post meal.
Weeks 7-12500 mcg 3x/dayAM/PM fasted, MidDay post meal.

Alternative example from the source dataset; not an approved-label regimen unless marked above.

Protocol logic check

Protocol context: GH-axis protocols are not 'more is better.' The logic is pulse quality, recovery time, IGF-1/glucose monitoring, and avoiding receptor desensitization, edema, appetite spikes, numbness, or blood-pressure strain. Entry context: target (GHRH); route Subcutaneous; timing Pre-Bed Fasted. Unapproved or source-dataset dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. GH-axis stacking should be filtered for total IGF-1/glucose burden, not just expected synergy.

Independent evidence

Independent safety notes: FDA lists CJC-1295 among withdrawn nominated bulk substances with potential significant safety risks, limited clinical data, and serious adverse events reported.

Regulatory status: unapproved or compounded peptide with FDA safety risk flag

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

  • Active cancer or history of malignancy: GH elevation accelerates cell proliferation; contraindicated in any hormone-sensitive or actively growing tumor.
  • High risk of tumor growth: subjects with pre-cancerous conditions, strong family history of growth-hormone sensitive cancers, or elevated cancer biomarkers.
  • Active acromegaly or other conditions involving excess endogenous GH or IGF-1.
  • Diabetic ketoacidosis: acute metabolic instability precludes GH-axis manipulation.
  • Uncontrolled diabetes mellitus or significant insulin resistance: IGF-1 elevation from GH stimulation worsens glucose metabolism.
  • Pregnancy: safety not established; GH axis stimulation during pregnancy is not advised.
  • Breastfeeding: safety not established.
  • Known hypersensitivity to CJC-1295 or any formulation excipients.
  • Concurrent use with CJC-1295 DAC, tesamorelin, sermorelin, or HGH 191aa: direct GHRH receptor competition or redundant GH axis overstimulation.
  • Concomitant glucocorticoid therapy at high doses: glucocorticoids blunt pituitary GH response and inhibit IGF-1 production.
  • Disruption of the hypothalamic-pituitary axis (e.g., pituitary adenoma, cranial radiation history): GHRH-R stimulation may be unpredictable.
  • Pediatric use in children with closed growth plates: inappropriate bone growth stimulation risk.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

  • Head rush and transient facial flushing immediately following injection: caused by acute GH pulse-induced vasodilation; typically resolves within 15-30 minutes.
  • Water retention and mild peripheral edema: GH-mediated sodium and fluid retention; most pronounced in the first 2-4 weeks and in higher-dose protocols.
  • Mild fatigue or lethargy: transient, typically occurs within 30-60 minutes post-injection; associated with the acute GH pulse.
  • Headache: related to vasodilation from the GH pulse; common in the first 1-2 weeks; diminishes with continued use.
  • Dizziness or lightheadedness: transient; associated with acute GH-mediated vasodilation.
  • Tingling or numbness in hands and feet: paresthesia from GH-related fluid shifts; more common at higher doses.
  • Vivid dreams: GH elevation during the nocturnal sleep cycle intensifies REM-phase dream vividness.
  • Joint stiffness: GH-mediated fluid in periarticular tissue; common at higher dose levels.
  • Mild hypoglycemia: possible when combined with fasting and a GHRP; GH pulse temporarily shifts glucose partitioning toward fat oxidation.
  • Increased appetite: modest; GH elevation has mild orexigenic effects.
  • Mild transient blood pressure elevation: secondary to GH-induced sodium retention; generally within normal range.
  • Injection site irritation: redness, swelling, or discomfort at subcutaneous administration site.
  • Pituitary desensitization with continuous use beyond cycle length: GH response attenuates if 12-16 week cycle limit is exceeded without washout.
  • Blunted efficacy from insufficient fasting: eating carbs or fats within 2 hours of injection significantly reduces or eliminates the GH pulse; not a side effect per se but the primary compliance failure point.

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

IpamorelinGHRP-2GHRP-6AOD-9604

Reported contraindicated combinations:

CJC-1295 DACSermorelinTesamorelinHGH 191AA (Somatropin)

Sources